Patents by Inventor Clark Pan

Clark Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11976112
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: May 7, 2024
    Assignee: Genzyme Coporation
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • Publication number: 20240117071
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Application
    Filed: June 21, 2023
    Publication date: April 11, 2024
    Inventors: Luis AVILA, Clark PAN, Huawei QIU, Qun ZHOU
  • Publication number: 20240059793
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Application
    Filed: May 17, 2023
    Publication date: February 22, 2024
    Inventors: Luis AVILA, Clark PAN, Huawei QIU, Qun ZHOU
  • Publication number: 20230365954
    Abstract: The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., ?-galactosidase A (?-Gal A), glucocerebrosidase (GCB), ?-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.
    Type: Application
    Filed: May 24, 2023
    Publication date: November 16, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Brian Dwyer, Bohong Zhang, Jun Hu, Muthuraman Meiyappan, Thomas Miller, Paul McLean, Clark Pan
  • Patent number: 11807690
    Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: November 7, 2023
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
  • Publication number: 20230340057
    Abstract: The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlling serum calcium levels with the PTH variants and compositions of the invention. The invention further relates to methods of treating hypoparathyroidism and/or hypocalcemia due to hypoparathyroidism with the PTH variants and compositions of the invention.
    Type: Application
    Filed: March 2, 2023
    Publication date: October 26, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Clark PAN, Angela NORTON, Kevin HOLMES, David LLOYD, Bryan GOODWIN, Rongxin SHI, Sujit JAIN, Chuan SHEN
  • Patent number: 11697690
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: July 11, 2023
    Assignee: GENZYME CORPORATION
    Inventors: Luis Avila, Clark Pan, Huawei Qiu, Qun Zhou
  • Patent number: 11685912
    Abstract: The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., ?-galactosidase A (?-Gal A), glucocerebrosidase (GCB), ?-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: June 27, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Brian Dwyer, Bohong Zhang, Jun Hu, Muthuraman Meiyappan, Thomas Miller, Paul McLean, Clark Pan
  • Patent number: 11660328
    Abstract: GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: May 30, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Clark Pan, Angela Norton, Bettina Strack-Logue, Clément Olivier
  • Publication number: 20230126645
    Abstract: Described herein are compositions of Thyroid Stimulating Hormone (TSH), wherein at least one polyalkylene glycol polymer is attached to a carbohydrate site of the TSH. Also described are compositions of mutated Thyroid Stimulating Hormone (TSH) and at least one polyalkylene glycol polymer, wherein the mutated TSH comprises a TSH in which one or more amino acid residues has been substituted with cysteine residue, and the polyalkylene glycol polymer is attached to the mutated TSH at the site of the substituted cysteine residue. Pharmaceutical compositions comprising these TSH compositions and method of treating a thyroid condition in a patient in need thereof, by administering to the patient an effective amount of the pharmaceutical compositions are also described.
    Type: Application
    Filed: May 23, 2022
    Publication date: April 27, 2023
    Applicant: GENZYME CORPORATION
    Inventors: Clark PAN, Huawei QIU, Sunghae PARK
  • Patent number: 11634468
    Abstract: The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlling serum calcium levels with the PTH variants and compositions of the invention. The invention further relates to methods of treating hypoparathyroidism and/or hypocalcemia due to hypoparathyroidism with the PTH variants and compositions of the invention.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: April 25, 2023
    Assignee: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Clark Pan, Angela Norton, Kevin Holmes, David Bruce Lloyd, Bryan James Goodwin, Rongxin Shi, Sujit Jain, Chuan Shen
  • Publication number: 20230031280
    Abstract: Described are fusion proteins of GLP-2 with an Fc region of immunoglobulin. The GLP-2 and Fc regions are separated by a linker comprised of amino acids. The fusion proteins persist and remain active in the body for longer periods of time than GLP-2 itself. Methods are disclosed of using the fusion proteins to treat and prevent enterocutaneous fistulae, radiation damage to the gastrointestinal tract, obstructive jaundice, and short bowel syndrome.
    Type: Application
    Filed: April 15, 2022
    Publication date: February 2, 2023
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Clark Pan, Angela Norton, Bettina Strack-Logue
  • Publication number: 20220363740
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Application
    Filed: April 4, 2022
    Publication date: November 17, 2022
    Applicant: GENZYME CORPORATION
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • Publication number: 20220153841
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Application
    Filed: October 26, 2021
    Publication date: May 19, 2022
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • Patent number: 11325971
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: May 10, 2022
    Assignee: Genzyme Corporation
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • Publication number: 20220119547
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Application
    Filed: March 29, 2021
    Publication date: April 21, 2022
    Inventors: Luis AVILA, Clark PAN, Huawei QIU, Qun ZHOU
  • Publication number: 20220089763
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Application
    Filed: August 17, 2021
    Publication date: March 24, 2022
    Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
  • Patent number: 11186638
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 30, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • Patent number: 11130816
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: September 28, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
  • Publication number: 20210169986
    Abstract: GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 10, 2021
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Clark PAN, Angela Norton, Bettina STRACK-LOGUE, Clément OLIVIER